TANIA: A Randomized Phase III Trial Evaluating Continued and Reintroduced Bevacizumab (BEV) in Patients Previously Treated with 1st-Line BEV for Locally Recurrent/Metastatic Breast Cancer (LR/mBC).

被引：0
|
作者：
von Minckwitz, G. [1 ]
Cortes, J. [1 ]
Gligorov, J. [1 ]
Marschner, N. W. [1 ]
Puglisi, F. [1 ]
Vrdoljak, E. [1 ]
Duenne, A-A [1 ]
Zielinski, C. [1 ]
机构：
[1] GBG Forsch GmbH, German Breast Grp, Neu Isenburg, Germany
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/0008-5472.SABCS11-OT3-01-04
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT3-01-04
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer
    Vrdoljak, E.
    Marschner, N.
    Zielinski, C.
    Gligorov, J.
    Cortes, J.
    Puglisi, F.
    Aapro, M.
    Fallowfield, L.
    Fontana, A.
    Inbar, M.
    Kahan, Z.
    Welt, A.
    Levy, C.
    Brain, E.
    Pivot, X.
    Putzu, C.
    Gonzalez Martin, A.
    de Ducla, S.
    Easton, V.
    von Minckwitz, G.
    ANNALS OF ONCOLOGY, 2016, 27 (11) : 2046 - 2052
  • [32] A randomized, placebo-controlled phase II study of AMG 386 plus bevacizumab (Bev) and paclitaxel (P) or AMG 386 plus P as first-line therapy in patients (pts) with HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC)
    Dieras, V.
    Jassem, J.
    Dirix, L. Y.
    Guastalla, J. P.
    Bono, P.
    Hurvitz, S. A.
    Goncalves, A.
    Romieu, G.
    Limentani, S. A.
    Jerusalem, G. H. M.
    Lakshmaiah, K.
    Roche, H. H.
    Sanchez-Rovira, P.
    Pienkowski, T.
    Segui-Palmer, M. A.
    Li, A.
    Sun, Y.
    Pickett-Gies, C. A.
    Wildiers, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [33] Impact of post-progression therapy on overall survival (OS) in the IMELDA randomized phase III trial evaluating the addition of capecitabine (CAP) to maintenance bevacizumab (BEV) for HER2-negative metastatic breast cancer (mBC)
    Mustacchi, G.
    Bines, J.
    Alba, E.
    Cortes, P.
    Doval, D.
    de Ducla, S.
    Button, P.
    Gligorov, J.
    CANCER RESEARCH, 2017, 77
  • [34] Capecitabine (Cap) combined with bevacizumab (Bev) with or without vinorelbine (Vin) in first-line metastatic breast cancer (MBC): First safety results from the randomized CARIN trial
    Hegewisch-Becker, S.
    Lerchenmuller, C. A.
    Welt, A.
    Decker, T.
    Just, M.
    Steffens, C.
    Hipper, A.
    Marschner, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [35] FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase III TRIBE trial by GONO group.
    Falcone, Alfredo
    Cremolini, Chiara
    Masi, Gianluca
    Lonardi, Sara
    Zagonel, Vittorina
    Salvatore, Lisa
    Trenta, Patrizia
    Tomasello, Gianluca
    Ronzoni, Monica
    Ciuffreda, Libero
    Zaniboni, Alberto
    Tonini, Giuseppe
    Buonadonna, Angela
    Valsuani, Chiara
    Chiara, Silvana
    Carlomagno, Chiara
    Boni, Corrado
    Marcucci, Lorenzo
    Boni, Luca
    Loupakis, Fotios
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [36] Bevacizumab (bev) in combination with capecitabine (cape) for the first-line treatment of elderly patients with metastatic colorectal cancer (mCRC): Results of a randomized international phase III trial (AVEX)
    Cunningham, David
    Lang, Istvan
    Lorusso, Vito
    Ocvirk, Janja
    Shin, Dongbok
    Jonker, Derek J.
    Osborne, Stuart
    Andre, Niko Alexander
    Waterkamp, Daniel
    Saunders, Mark P.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [37] Final overall survival (OS) and safety analyses of RIBBON-2, a randomized phase III trial of bevacizumab (BEV) versus placebo (PL) combined with second-line chemotherapy (CT) for HER2-negative BEV-naive metastatic breast cancer (MBC).
    Brufsky, Adam M.
    Hurvitz, Sara A.
    Perez, Edith A.
    Yamamoto, Hideharu
    Valero, Vicente
    O'Neill, Vincent
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27)
  • [38] AVEREL: a randomized Phase III trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer
    不详
    BREAST CANCER MANAGEMENT, 2013, 2 (04) : 274 - 274
  • [39] AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer
    Gianni, Luca
    Romieu, Gilles H.
    Lichinitser, Michail
    Serrano, Sergio V.
    Mansutti, Mauro
    Pivot, Xavier
    Mariani, Paola
    Andre, Fabrice
    Chan, Arlene
    Lipatov, Oleg
    Chan, Stephen
    Wardley, Andrew
    Greil, Richard
    Moore, Nicola
    Prot, Sylvie
    Pallaud, Celine
    Semiglazov, Vladimir
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (14) : 1719 - +
  • [40] FIRST EFFICACY RESULTS FROM THE TURANDOT PHASE III TRIAL COMPARING TWO BEVACIZUMAB (BEV)-CONTAINING REGIMENS AS FIRST-LINE THERAPY FOR HER2-NEGATIVE METASTATIC BREAST CANCER (MBC)
    Zielinski, C.
    Lang, I.
    Inbar, M.
    Kahan, Z.
    Greil, R.
    Beslija, S.
    Stemmer, S. M.
    Kaufman, B.
    Zvirbule, Z.
    Steger, G.
    Melichar, B.
    Pienkowski, T.
    Sirbu, D.
    Petruzelka, L.
    Eniu, A.
    Nisenbaum, B.
    Dank, M.
    Anghel, R.
    Messinger, D.
    Brodowicz, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 116 - 116
12345